Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)

Otto S. Hoekstra

Amsterdam, NH, NL 
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Otto Hoekstra practices in Amsterdam, Netherlands. Mr. Hoekstra is rated as a Distinguished expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 228 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Gender
Male

Locations

Amsterdam, NH 1081HV, Netherlands
Other Locations
Groningen, GR, Netherlands
Utrecht, UT, Netherlands
Noord, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2

228 Total Publications

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.
Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.
Journal: Scientific reports
Published: December 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoekstra's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile